View Single Post
  #4  
Old Sun Dec 12, 2010, 03:42 PM
akita akita is offline
Member
 
Join Date: Nov 2010
Posts: 110
ASH 2010 Two screening tests for immune thrombocytopenia component in MDS-Patients

Hi Lindy,

This study -

http://ash.confex.com/ash/2010/webpr...aper34476.html | Author

2943 Platelet-Associated IgG May Be Associated with Thrombocytopenia In Patients with Myelodysplastic Syndromes

- found out that MPV was significantly higher in patients with platelet count < 100 x109/L( median, min-max: 9.38, 6.9-23.1 vs *8.46, 4.88-12.83 ; p<0.001, Wilcoxon rank sum test).

Your doctor can relatively easily find out if you belong to the group of MDS-patients where immune destruction of platelets could be an additional factor in the genesis of thrombocytopenia.

"Thus, we propose that a combination of a simple index as MPV and a highly sensitive and easy to perform screening test for PAIgG as PIFT could be applied to select a subset of MDS patients in which we would be able to prevent the overuse of unnecessary platelet transfusions and who could be candidates for an immunosuppressive therapeutic approach. "

ITP could be an approach helping you to get medicaments like NPlate, but the actual studies seem not promising the optimum of safety for MDS-patients.

Hope i could help.

Regards,

Margarete
__________________
Margarete, 54, living in Vienna, Austria,
MDS/AML M2, diagnosed 9/2007, then Chemos, aSZT 4/2008, chronic GVHD
Reply With Quote